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Introduction
The mucin 1 (MUC1) heterodimeric protein is aberrantly overexpressed by breast, lung and other types of carcinomas, and has been recognized as an attractive cancer target (1, 2) . Studies on the oncogenic function of MUC1 were advanced by the demonstration that MUC1 consists of two subunits (1) . The transmembrane MUC1-C subunit interacts with receptor tyrosine kinases, such as EGFR and HER2, at the cell membrane and contributes to activation of their downstream signaling pathways (3) (4) (5) . The MUC1-C cytoplasmic domain interacts with the WNT pathway effector, β-catenin, and promotes the activation of WNT target genes in a nuclear complex with TCF7L2/TCF4 (5-7). MUC1-C also interacts with additional transcription factors, including NF-κB and STAT3, in the regulation of gene expression (5) . The involvement of MUC1-C with effectors that have been linked to transformation (5) and the demonstration that MUC1-C drives self-renewal of cancer cells (8) (9) (10) have provided support for the development of agents that block MUC1-C function. In this respect, the MUC1-C cytoplasmic domain contains a CQC motif that is necessary and sufficient for MUC1-C homodimerization (5) . Additionally, mutation of the CQC motif to AQA blocks the capacity of MUC1-C to interact with diverse effectors and function as an oncoprotein (11) . Based on these observations, a novel class of cell-penetrating peptides was developed to bind to the CQC motif and thereby block MUC1-C homodimerization and signaling (12, 13).
The MUC1-C targeted peptides induce death of MUC1-expressing cancer cells in vitro and inhibit growth of established tumor xenografts in mice (12, 14, 15) . As shown for other small therapeutic peptides (16) , the MUC1-C inhibitor peptides exhibited short circulating half-lives and thus required daily administration for sustained inhibition of tumor growth in mouse models (12, 14, 15) . These findings provided the basis for Phase I evaluation of the lead MUC1-C inhibitor peptide, designated GO-203, in patients with refractory solid tumors.
Cell-penetrating anti-cancer peptides are emerging as promising agents to target intracellular proteins that are otherwise undruggable with small molecule inhibitors. For example, peptide drugs are under delivery of peptides to tumors can be challenging because of unfavorable pharmacokinetic parameters (16) . Administration of peptide drugs can also be limited by their proteolytic degradation or the induction of immune responses. Accordingly, improved delivery systems are needed, at least in part, for the successful development of anticancer peptides. Nanoparticles (NPs) have been employed to improve the pharmacokinetic properties and therapeutic indices of small molecule anti-cancer agents, such as doxorubicin and paclitaxel (22) . In this way, NPs have the capacity to sustain drug exposure in the tumor microenvironment by the enhanced permeation and retention (EPR) effect (23) . In addition, NPs can be modified with ligands that bind to targets selectively expressed on the surface of tumor cells (24) . Among different classes of NPs, polylactic acid (PLA)-polyethylene glycol (PEG) block copolymer NPs are non-toxic and biodegradable (24) .
In addition, the polymeric PLA-PEG NPs have been administered clinically for the delivery of small molecule anti-cancer agents (24) .
By contrast and to our knowledge, polymeric NPs have not been explored for the delivery of anti-cancer peptides, other than in a recent preclinical study (25) . In this regard, anti-cancer peptides have been incorporated into cationic liposomes (26) , perfluorocarbon nanoemulsion vehicles (27) , cyclodextrin polymerized NPs (28) , and liposomeprotamine-heparin NPs (29) . However, unlike polymeric NPs, these NP 
Materials and Methods
Preparation of GO-203-loaded NPs. Polylactic acid (PLA)-polyethylene glycol (PEG)-polypropylene glycol (PPG)-PEG tetrablock copolymers were synthesized as described (25) . The NPs were loaded with and filtered through an Amikon 10-kDa ultrafilter (Millipore). The filtrate was collected and analyzed for free peptide using a Micro-BCA Kit (Pierce Chemicals). Encapsulation efficiency (EE), particle size and zeta potential were determined as described (25) .
Assessment of GO-203 release from NPs. The in vitro release kinetics of GO-203 from NPs were determined by the ultrafiltration method as described (25) . Analysis of cell viability. Cells were seeded on 96-well plates in 100 μl growth medium at a density of 1000-2000 cells per well.
After 24 h, the cells were exposed to one treatment of NPs on day 0 or two treatments of NPs on day 0 and 3. Cell viability was determined in triplicates using the Alamar blue assay on day 3 or 7. Statistical significance between treatment groups was assessed using the Student's t-test.
Immunoblot analysis. Cell lysates were prepared as described (15) . Soluble proteins were analyzed by immunoblotting with anti-MUC1-
Research. Technologies), or anti-β-actin (Sigma) as described (15) . Immune complexes were detected with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (PerkinElmer). Table S1 ). Thus, the encapsulation efficiency of GO-203 in PLA-PEG 4000 NPs was higher than that obtained with PLA-PEG 600 NPs (Supplemental Table S1 ). We also found that increases in PEG chain length improved the GO-203 encapsulation efficiency (Supplemental Table S1 ). We next studied the MUC1-C homodimerization. As found with non-encapsulated GO-203 (13), treatment with GO-203/NPs was associated with inhibition of MUC1-C homodimer formation (Fig. 3A) , indicating that delivery of NPs to these carcinoma cells results in MUC1-C targeting. MUC1-C promotes expression of the p53-inducible regulator of glycolysis and apoptosis (TIGAR) (35) , which shunts glucose-6-phosphate into the pentose phosphate pathway (PPP) (36) . Consistent with targeting MUC1-C, we found that treatment of ZR-75-1 cells with GO-203/NPs is associated with suppression of TIGAR levels (Fig. 3B) . Moreover, addition of the antioxidant NAC blocked GO-203/NP-induced TIGAR suppression (Fig. 3B) , in concert with a ROS-mediated mechanism. TIGAR promotes the production of NADPH and GSH by the PPP (36) . In this way, targeting MUC1-C with GO-203/NPs was also associated with marked decreases in NADPH (Fig. 3C , left) and GSH (Fig. 3C , right) levels.
Measurement of NADPH and GSH
Moreover, and consistent with these results, we found that treatment with GO-203/NPs, but not CP-2/NPs, results in induction of phospho-p38 (Fig. 3D) , which is activated in response to disruption of redox balance (37). (Fig. 4A, left) .
GO-
Other studies performed with H460/KRAS(Q61H) NSCLC cells further demonstrated that GO-203/NPs are active in the setting of mutant KRAS expression (Fig. 4A, right) . By contrast, exposure of H1975 and H460 NSCLC cells to empty NPs was associated with substantially lower levels of cell death that were not significantly different from those obtained for ZR-75-1 and MDA-MB-468 breast cancer cells (Fig. 2A, left and right). As shown for breast cancer cells, we also found that treatment of H1975 cells with GO-203/NPs is associated with disruption of MUC1-C homodimers (Fig. 4B, left) . Moreover, GO-203 treatment resulted in downregulation of TIGAR (Fig. 4B, right) and decreases in NADPH (Fig.   4C , left) and GSH (Fig. 4C, right) levels. Treatment of H1975 cells with GO-203/NPs was also associated with activation of p-p38 (Fig. 4D) 
GO-203/NPs inhibit breast and lung cancer cell self-renewal.
Disruption of redox balance inhibits the capacity of cancer cells to undergo self-renewal (38) . Accordingly, we first investigated the effects of GO-203/NPs on clonogenic survival of ZR-75-1 cells.
Treatment with the GO-203/NPs, but not the empty NPs, was highly effective in inhibiting colony formation (Fig. 5A, left) . Similar results were obtained with GO-203/NP treatment of MDA-MB-468 (Fig. 5A,   middle ) and MCF-7 (Fig. 5A, right) As expected from previous studies (9), the control MDA-MB-468 cells formed mammospheres (Fig. 5B) . Morevoer, treatment with GO-203/NPs, but not CP-2/NPs, was highly effective in inhibiting mammosphere formation and decreasing sphere-forming efficiency (SFE) (Fig. 5B) .
GO-203/NPs also inhibited MCF-7 mammosphere formation (Fig. 5C the kinetics of GO-203 release from the NPs over 7 days (Fig. 1C) , we treated the Ehrlich tumor bearing mice IP once a week for 3 weeks with doses of 10, 15 or 20 mg/kg GO-203/NPs (Fig. 6B) . As compared to the control mice, treatment with 10 mg/kg GO-203/NPs was associated with partial slowing of Ehrlich tumor growth (Fig. 6B) . By contrast, IP dosing of 15 and 20 mg/kg GO-203/NPs resulted in complete inhibition of Ehrlich tumor growth, supporting a dose-response effect (Fig. 6B) . In previous studies of nude mice bearing subcutaneous NSCLC xenografts, treatment with non-encapsulated 30 mg/kg GO-203 IP daily for 21 days was associated with complete regressions (15) . In the present work, IP administration of GO-203 each day at a dose of 18 mg/kg was also effective in the treatment of ZR-75-1 xenografts (Fig. 6C) There is presently limited information about the optimal conditions for encapsulating peptides into polymeric NPs and the copolymers used will likely vary depending on the peptidyl drug itself.
The approach we used in the present work was based upon a recent experience in which we encapsulated the anticancer peptide NuBCP-9 into tetrablock PLA-(PEG-PPG-PEG) 12.5K copolymers (25) . The PLA-PEG copolymer is a bilayer structure with a PLA hydrophobic core and a PEG hydrophilic shell interacting with the aqueous medium. The importance of the tetrablock structure is that conjugation of PEG-PPG-PEG with PLA extends the hydrophobic core and thereby has the capacity for increasing peptide uptake and sustaining its release (25) . The PLA-PEG-PPG-PEG formulation was thus selected based on the findings demonstrating that (i) peptide encapsulation is greater than that obtained with PLA, and (ii) peptide release is more sustained compared to that found for the PLA-PEG NPs (25) . Indeed, as compared to PLAbased NPs, we found that loading of GO-203 is increased with PLA-PEG-PPG-PEG NPs. We also found that approximately 50% of the GO-203
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